Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.

Abstract

In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. Patients treated with ethoglucid (n = 39) received 0.565 g (1% solution) ethoglucid weekly for 6 weeks and then monthly for 1 year. Patients treated with KLH (n = 38) were immunised subcutaneously with 1 mg KLH; bladder instillations of 30 mg were then given weekly for 6 weeks and thereafter monthly for 1 year. The recurrence rates, disease-free intervals and tumour progression rates were evaluated. The end-point of the study was either progression in stage or grade or more than 1 recurrence during the observation period. The minimum length of follow-up was 1 year. The recurrence rates, mean disease-free intervals and progression rates in the 2 groups showed no statistically significant differences.

• Authors: J Flamm, A Bucher
• Journal: British journal of urology (Br J Urol) Vol. 67 Issue 1 Pg. 70-3 (Jan 1991) ISSN: 0007-1331 [Print] England
• PMID: 1993279 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Ethoglucid
• Hemocyanins
• keyhole-limpet hemocyanin

Topics

• Administration, Intravesical
• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Transitional Cell (surgery, therapy)
• Combined Modality Therapy
• Ethoglucid (therapeutic use)
• Female
• Hemocyanins (therapeutic use)
• Humans
• Immunotherapy
• Male
• Middle Aged
• Neoplasm Recurrence, Local (prevention & control)
• Prospective Studies
• Risk Factors
• Urinary Bladder Neoplasms (surgery, therapy)